Cedermark B J, Gunven P, Hammarberg C
J Surg Oncol. 1983 Feb;22(2):125-8. doi: 10.1002/jso.2930220216.
Forty-one patients with measurable advanced gastrointestinal malignancy were treated with a combination of Adriamycin (doxorubicin), 5-FU (5-fluorouracil), and CCNU (1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea). The response to therapy was evaluated every eight weeks. In addition to standard clinical examinations and laboratory tests to evaluate toxicity, 31 patients were asked to rank both the expected and experienced negative effects of the treatment. Although both patients with hepatocellular cancer and the patient with a soft tissue sarcoma responded to the regimen, only 1 of 38 patients with adenocarcinoma had a favourable response. The clinically measurable toxicity, principally to the gastrointestinal tract and bone marrow, was relatively mild. However, the patients' subjective evaluation of their treatment made the side effects appear more significant. The results suggest that this regimen deserves further evaluation in patients with hepatocellular cancer and soft tissue sarcomas.
41例患有可测量的晚期胃肠道恶性肿瘤的患者接受了阿霉素（多柔比星）、5-氟尿嘧啶和环己亚硝脲（1-(2-氯乙基)-3-环己基-1-亚硝基脲）联合治疗。每八周评估一次治疗反应。除了进行标准的临床检查和实验室测试以评估毒性外，还要求31名患者对治疗的预期和实际负面影响进行排名。虽然肝细胞癌患者和软组织肉瘤患者对该方案均有反应，但38例腺癌患者中只有1例有良好反应。临床上可测量的毒性主要针对胃肠道和骨髓，相对较轻。然而，患者对治疗的主观评价使副作用显得更为明显。结果表明，该方案值得在肝细胞癌和软组织肉瘤患者中进一步评估。
